Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related TEVA
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Benzinga's Weekend M&A Chatter
Bristol-Myers Beats on Q4 Earnings, 2015 View Disappoints - Analyst Blog (Zacks)
Related QEP
Markets Inch Higher Following Encouraging Beige Book Commentary
Worst Performing Industries For November 28, 2014
QEP Midstream Partners: 20% Near-Term Upside In A Takeout, And 40-60% Longer Term (Seeking Alpha)

Analysts at JP Morgan downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “overweight” to “neutral.” The target price for Teva has been lowered from $45 to $43. Teva's shares closed at $38.88 yesterday.

Deutsche Bank downgraded QEP Resources (NYSE: QEP) from “buy” to “hold.” The target price for QEP Resources has been lowered from $37 to $34. QEP Resources' shares closed at $28.78 yesterday.

Baird downgraded Brady (NYSE: BRC) from “outperform” to “neutral.” The target price for Brady has been lowered from $41 to $33. Brady's shares closed at $30.52 yesterday.

Analysts at DA Davidson downgraded Under Armour (NYSE: UA) from “buy” to “neutral.” Under Armour's shares closed at $80.59 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Jan 2015JefferiesMaintainsBuy
Dec 2014Sterne AgeeUpgradesNeutralBuy
Dec 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BRC + QEP)

Around the Web, We're Loving...

Get Benzinga's Newsletters